AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22960586 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing fluid intake (n = 44)
Number of subjects: 74
Study 22960586 — intervention group
Group type: COMPARATOR
Intervention: Maintenance group (n = 30)
Number of subjects: 74
Study 20969563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous cream
Number of subjects: 20
Study 20969563 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 white soft paraffin and liquid paraffin
Number of subjects: 20
Study 20969563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprobase(®)
Number of subjects: 20
Study 20969563 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaderm(®)
Number of subjects: 20
Study 20969563 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment and cream
Number of subjects: 20
Study 20969563 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical agent)
Number of subjects: 20
Study 18280960 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 12
Study 18280960 — intervention group
Group type: COMPARATOR
Intervention: Inlay Bone Grafting (Inlay)
Number of subjects: 12
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood asthma debut at younger than 5 years
Number of subjects: 9812
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or more asthma symptoms in adults
Number of subjects: 9812
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma medication in adults
Number of subjects: 9812
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hay fever in adults
Number of subjects: 9812
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy in adults
Number of subjects: 9812
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE to cat in adults
Number of subjects: 9812
Study 16950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet removal between surveys to reduce allergen
Number of subjects: 9812
Study 12661143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 gram intramuscularly at 24‐hour intervals
Number of subjects: 71
Study 12661143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 71
Study 12661143 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent urinary tract infection
Number of subjects: 71
Study 10721928 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based dietary intervention
Number of subjects: 137
Study 10721928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study 8845572 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with melphalan and prednisone
Number of subjects: 0
Study 8845572 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with melphalan
Number of subjects: 0
Study 8845572 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with interferon alpha
Number of subjects: 0
Study 8845572 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment for MM patients who are primary refractory to melphalan
Number of subjects: 0
Study 8845572 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with melphalan and prednisone
Number of subjects: 0
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: cefadroxil 1 g tid (13 subjects)
Number of subjects: 71
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole 160/800 mg bd (23 subjects)
Number of subjects: 71
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin 400 mg bd (35 subjects)
Number of subjects: 71
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (all agents)
Number of subjects: 71
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adequate mobility and normal renal function
Number of subjects: 71
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for men
Number of subjects: 71
Study 2079452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for women
Number of subjects: 71
Study 94209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 94209 — intervention group
Group type: COMPARATOR
Intervention: PGE2 and serotonin (injected intradermally in healthy volunteers)
Number of subjects: 0
Study 94209 — intervention group
Group type: COMPARATOR
Intervention: ADP (in vitro study)
Number of subjects: 0
Study 31500670 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1.8 g/day for 16 weeks
Number of subjects: 120
Study 31500670 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 120
Study 31500670 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 120
Study 31500670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n = 58)
Number of subjects: 88
Study 28195952 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 42)
Number of subjects: 88
Study 28195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and Usual care combined
Number of subjects: 88
Study 25557936 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 0
Study 25557936 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 0
Study 23065349 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Classroom® approach (RC)
Number of subjects: 83
Study 20798665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI; 15°C)
Number of subjects: 10
Study 20798665 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Water Immersion (NWI; 33°C)
Number of subjects: 10
Study 20798665 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; no immersion)
Number of subjects: 10
Study 20798665 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between CWI and NWI
Number of subjects: 10
Study 20798665 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 10
Study 20798665 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ghrelin levels
Number of subjects: 10
Study 18991063 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/m(3) UFP exposure
Number of subjects: 24
Study 18991063 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/m(3) UFP exposure
Number of subjects: 24
Study 18991063 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 24
Study 16817913 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2b and lamivudine combination
Number of subjects: 88
Study 16817913 — intervention group
Group type: COMPARATOR
Intervention: lamivudine monotherapy
Number of subjects: 88
Study 12956752 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (environmental control measures including vinyl flooring, allergen-impermeable cot mattress, hot-washable toy, mite allergen-impermeable encasings, high filtration vacuum cleaner)
Number of subjects: 278
Study 12956752 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 278
Study 12956752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 278
Study 10706509 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg fluticasone propionate (FP) b.i.d. delivered via Babyhaler spacer
Number of subjects: 48
Study 10706509 — intervention group
Group type: COMPARATOR
Intervention: Placebo delivered via Babyhaler spacer
Number of subjects: 48
Study 10706509 — intervention group
Group type: EXPERIMENTAL
Intervention: FP and placebo groups
Number of subjects: 48
Study 9153522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with progressive supranuclear palsy
Number of subjects: 10
Study 9153522 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 10
Study 8217354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF: cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 176
Study 8217354 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (control)
Number of subjects: 176
Study 8217354 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment after relapse
Number of subjects: 176
Study 8217354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy after relapse
Number of subjects: 176
Study 8217354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 176
Study 8217354 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CMF) and No adjuvant therapy (control)
Number of subjects: 176
Study 3304523 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive hydrocolloid dressing (Granuflex, Squibb Surgicare)
Number of subjects: 56
Study 3304523 — intervention group
Group type: COMPARATOR
Intervention: Porous non-adherent dressing (N A, Johnson and Johnson)
Number of subjects: 56
Study 31576565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 260
Study 31576565 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 260
Study 30160521 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum triglycerides
Number of subjects: 5042
Study 30160521 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quintile (>185 mg/dl)
Number of subjects: 5042
Study 27157575 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12
Number of subjects: 30
Study 27157575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (heat-treated fermented milk without probiotic bacteria or dietary fiber)
Number of subjects: 30
Study 27157575 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic fermented milk
Number of subjects: 30
Study 27157575 — intervention group
Group type: COMPARATOR
Intervention: Synbiotic and placebo
Number of subjects: 30
Study 24941843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangfei Liganning Tablet (DLT), two tablets each time, three times per day for 4 weeks
Number of subjects: 80
Study 24941843 — intervention group
Group type: COMPARATOR
Intervention: Liver‐protecting Tablet (LT), four tablets each time, three times per day for 4 weeks
Number of subjects: 80
Study 22502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (e.g., agreeableness, extraversion, stress, social support, self-efficacy)
Number of subjects: 1500
Study 22502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to greater social support
Number of subjects: 1500
Study 22502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived stress
Number of subjects: 1500
Study 22502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1500
Study 22502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-patient communication and physical environment
Number of subjects: 1500
Study 21098355 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive version of the manuscript
Number of subjects: 238
Study 21098355 — intervention group
Group type: COMPARATOR
Intervention: No-difference version of the manuscript
Number of subjects: 238
Study 18482155 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone monotherapy (50 mg naltrexone + sertraline placebo)
Number of subjects: 101
Study 18482155 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + sertraline (100 mg) plus nine sessions of medical management and supportive advice
Number of subjects: 101
Study 15672052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 61
Study 15672052 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 61
Study 12886816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation (vitamin A, 1000 micrograms; vitamin B1, 1.4 mg; vitamin B2, 1.6 mg; vitamin B6, 1.7 mg; vitamin B12, 2.0 micrograms; folate, 150 micrograms; niacin, 16 mg; vitamin C, 50 mg; vitamin D, 5 micrograms; vitamin E, 8 mg; iron, 18 mg; zinc, 20 mg; copper, 2.0 mg; iodine, 150 micrograms; selenium, 40 micrograms)
Number of subjects: 977
Study 12886816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 977
Study 12886816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 977
Study 10229998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance training (12 weeks, 3 times a week, 3 x 10 repetitions at 80% of 1RM)
Number of subjects: 9
Study 10229998 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no training)
Number of subjects: 9
Study 10229998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance training
Number of subjects: 9
Study 8890674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive medication (lithium, perphenazine, or paroxetine)
Number of subjects: 158
Study 8890674 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive medication
Number of subjects: 158
Study 1422291 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine spray with frigen, two applications (20 mg lidocaine)
Number of subjects: 130
Study 1422291 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylestesin spray with frigen, two applications (14 mg lidocaine)
Number of subjects: 130
Study 1422291 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylestesin spray with frigen, three applications (21 mg lidocaine)
Number of subjects: 130
Study 1422291 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylestesin pump spray without frigen, two applications (14 mg lidocaine)
Number of subjects: 130
Study 1422291 — intervention group
Group type: COMPARATOR
Intervention: No topical anesthesia
Number of subjects: 130
Study 4084667 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone hemisuccinate 1200 mg
Number of subjects: 0
Study 4084667 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone hemisuccinate 75 mg
Number of subjects: 0
Study 4084667 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone hemisuccinate (both doses)
Number of subjects: 0
Study 30085292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (40 IU)
Number of subjects: 48
Study 30085292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 48
Study 29661241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT-O)
Number of subjects: 80
Study 29661241 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 27712772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention
Number of subjects: 3126
Study 27712772 — intervention group
Group type: COMPARATOR
Intervention: Not assigned to an active sodium intervention
Number of subjects: 3126
Study 27712772 — intervention group
Group type: EXPERIMENTAL
Intervention: Average sodium intake categories (<2,300, 2,300 to <3,600, 3,600 to <4,800, and ≥4,800 mg/24 h)
Number of subjects: 3126
Study 27712772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium/potassium ratio
Number of subjects: 3126
Study 24999963 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated SDMA (4th quartile, >1.38 μmol/L)
Number of subjects: 925
Study 23356027 — intervention group
Group type: COMPARATOR
Intervention: 1 year of WHO‐MDT (dapsone, clofazimine, rifampin)
Number of subjects: 198
Study 23356027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of WHO‐MDT plus an initial 1 month of daily ofloxacin
Number of subjects: 198
Study 23356027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of daily rifampin and daily ofloxacin
Number of subjects: 198
Study 23356027 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of WHO‐MDT
Number of subjects: 198
Study 23356027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of daily rifampicin and daily ofloxacin
Number of subjects: 198
Study 20228404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 5518
Study 20228404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5518
Study 18564278 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 40
Study 18564278 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment alone (Control)
Number of subjects: 40
Study 16403993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (50-100 mg daily)
Number of subjects: 30
Study 16403993 — intervention group
Group type: COMPARATOR
Intervention: Control (no lamotrigine)
Number of subjects: 30
Study 14657874 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 24
Study 14657874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10937983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lisinopril (2.5-5.0 mg/day)
Number of subjects: 3164
Study 10937983 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lisinopril (32.5-35.0 mg/day)
Number of subjects: 3164
Study 10937983 — intervention group
Group type: EXPERIMENTAL
Intervention: All cause mortality (primary endpoint)
Number of subjects: 3164
Study 10937983 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of all-cause hospitalisation or all-cause mortality (secondary endpoint)
Number of subjects: 3164
Study 8901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg)
Number of subjects: 29133
Study 8901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg)
Number of subjects: 29133
Study 8901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants smoking at least 20 cigarettes daily
Number of subjects: 29133
Study 8901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants smoking 5-19 cigarettes daily
Number of subjects: 29133
Study 8901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants with higher alcohol intake (> or = 11 g of ethanol/day)
Number of subjects: 29133
Study 8901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants with lower alcohol intake
Number of subjects: 29133
Study 2053632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 56
Study 2053632 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 56
Study 6753891 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25-50 mg three times daily)
Number of subjects: 57
Study 6753891 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 57
Study 6753891 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (25-50 mg once daily)
Number of subjects: 57
Study 6753891 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol + Hydrochlorothiazide (25-50 mg once daily)
Number of subjects: 57
Study 6753891 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 57
Study 6753891 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 57
Study 31049877 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (n = 137, 20 g of whey protein, 3 g of leucine, 800 IU VitD)
Number of subjects: 288
Study 31049877 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 151, isocaloric control product)
Number of subjects: 288
Study 31049877 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 288
Study 31049877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 288
Study 29855307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored retinal screening promotion leaflet
Number of subjects: 237
Study 26411392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion concept posterior-stabilized knee prosthesis (LOSPA)
Number of subjects: 44
Study 26411392 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior-stabilized knee prosthesis (P.F.C. Sigma)
Number of subjects: 44
Study 24913212 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Dance for Seniors (EXDASE) Program, performed once a week for 60 minutes for 3 months
Number of subjects: 0
Study 24913212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study 24913212 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Dance for Seniors (EXDASE) Program
Number of subjects: 0
Study 22207667 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program regarding the nature of temporomandibular disorder (TMD) and self-care measures
Number of subjects: 41
Study 22207667 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint
Number of subjects: 41
Study 20431381 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (70 mg/m loading dose on day 1, then 50 mg/m daily, maximum 70 mg/d)
Number of subjects: 82
Study 20431381 — intervention group
Group type: COMPARATOR
Intervention: L-AmB (3 mg/kg daily)
Number of subjects: 82
Study 20431381 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 82
Study 20431381 — intervention group
Group type: COMPARATOR
Intervention: L-AmB
Number of subjects: 82
Study 17570804 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-specific tailored materials
Number of subjects: 118
Study 17570804 — intervention group
Group type: COMPARATOR
Intervention: Widely used generic booklet about clinical trials
Number of subjects: 118
Study 15654776 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% crystal violet
Number of subjects: 400
Study 15654776 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% crystal violet
Number of subjects: 400
Study 15654776 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% methylene blue
Number of subjects: 400
Study 15654776 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% methylene blue
Number of subjects: 400
Study 12138325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg under fasting conditions
Number of subjects: 18
Study 12138325 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 400 mg under fed conditions
Number of subjects: 18
Study 10457579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mensendieck exercise program (20 group sessions over 13 weeks)
Number of subjects: 77